Entering text into the input field will update the search result below

Zynex, Inc. (ZYXI) Prepares for First Evaluation of New Blood Monitor

Apr. 13, 2011 10:53 AM ETZYXI
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Seeking Alpha Analyst Since 2008

QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net.

Yesterday, Zynex, Inc. announced that its new blood volume monitor medical device would be entering its first clinical evaluation, to be performed by OmniaVicinit, Llc. The device is being developed by Zynex Monitoring Solutions, a subsidiary.

Zynex is a provider of pain management systems and electrotherapy products for medical patients with functional disability. The company engineers, manufactures, markets and sells its own design of medical devices under three subsidiaries: Zynex Medical, Zynex Monitoring Solutions, and Zynex NeuroDiagnostic. The Zynex product line is FDA approved and is intended to improve quality of life for sufferers of strokes, spinal cord injuries and chronic pain.

The Zynex blood volume monitor is a device intended to detect blood loss during surgery and any internal bleeding during the recovery process. Zynex sees the device as fulfilling an unmet need in the medical industry, and believes it will lead to safer surgery and recovery monitoring. OmniaVicinit, the organization performing the product’s evaluation, facilitates development of clinical research programs, non-traditional clinical studies, as well as investigative site quality support.

Zynex’s CEO, Thomas Sandgaard, said, “We are very excited about the development and prototyping of our cardiac monitor for blood volume. We are starting the next phase of collecting data to further validate the algorithm used to non-invasively determine changes in central blood volume. We expect to use the data for defining further clinical studies, as well as to provide substantiation for FDA submission and international regulatory clearance.”

Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.